BioGaia is involved in the research and development of probiotics that support health and well-being across various life stages. Its probiotics are clinically proven.

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylorithe gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.

COM:BIOGAIA

BioGaia

Last Close

107.40

07/11 16:29

Market Cap

11.98B

Beta: -

Volume Today

74.64K

Avg: -

locale

market

industry

website

ipo date

peer of

Metrics